Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Transcriptomics Market, by Technology
1.4.2 North America Transcriptomics Market, by Application
1.4.3 North America Transcriptomics Market, by Component
1.4.4 North America Transcriptomics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021)
3.3.2 Key Strategic Move: (Acquisitions and Mergers: 2019, Jan – 2021, Apr) Leading Players
3.3.3 Key Strategic Move: (Product Launches ad Product Expansions: 2018, Mar – 2021, Nov) Leading Players
Chapter 4. North America Transcriptomics Market by Technology
4.1 North America q PCR Market by Country
4.2 North America Microarrays Market by Country
4.3 North America Sequencing Technology Market by Country
Chapter 5. North America Transcriptomics Market by Application
5.1 North America Drug Discovery Market by Country
5.2 North America Diagnostics & Disease Profiling Market by Country
5.3 North America Others Market by Country
Chapter 6. North America Transcriptomics Market by Component
6.1 North America Consumables Market by Country
6.2 North America Instruments Market by Country
6.3 North America Software Market by Country
6.4 North America Services Market by Country
Chapter 7. North America Transcriptomics Market by Country
7.1 US Transcriptomics Market
7.1.1 US Transcriptomics Market by Technology
7.1.2 US Transcriptomics Market by Application
7.1.3 US Transcriptomics Market by Component
7.2 Canada Transcriptomics Market
7.2.1 Canada Transcriptomics Market by Technology
7.2.2 Canada Transcriptomics Market by Application
7.2.3 Canada Transcriptomics Market by Component
7.3 Mexico Transcriptomics Market
7.3.1 Mexico Transcriptomics Market by Technology
7.3.2 Mexico Transcriptomics Market by Application
7.3.3 Mexico Transcriptomics Market by Component
7.4 Rest of North America Transcriptomics Market
7.4.1 Rest of North America Transcriptomics Market by Technology
7.4.2 Rest of North America Transcriptomics Market by Application
7.4.3 Rest of North America Transcriptomics Market by Component
Chapter 8. Company Profiles
8.1 Fluidigm Corporation
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Product Launches and Product Expansions:
8.2 Promega Corporation
8.2.1 Company Overview
8.3 General Electric (GE) Co. (GE Healthcare)
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expense
8.4 Merck & Co., Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expenses
8.5 Thermo Fisher Scientific, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Acquisition and Mergers:
8.5.6 SWOT Analysis
8.6 Illumina, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.7 Bio-Rad laboratories, Inc.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent strategies and developments:
8.7.5.1 Partnerships, Collaborations, and Agreements:
8.7.5.2 Product Launches and Product Expansions:
8.7.5.3 Acquisition and Mergers:
8.8 Agilent Technologies, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Acquisition and Mergers:
8.9 F. Hoffmann-La Roche Ltd.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expense
8.10. Qiagen N.V.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expense
8.10.5 Recent strategies and developments:
8.10.5.1 Partnerships, Collaborations, and Agreements:
8.10.5.2 Product Launches and Product Expansions:
8.10.5.3 Acquisition and Mergers:
Unique Offerings 